- Home
- CELH vs MRNA Comparison
CELH vs MRNA Comparison
Compare CELH & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | MRNA |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 11.5B |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CELH | MRNA |
|---|---|---|
| Price | $41.44 | $52.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 17 | 12 |
| Target Price | ★ $66.50 | $33.00 |
| AVG Volume (30 Days) | 5.4M | ★ 8.4M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 0.25 | N/A |
| Revenue | $1,318,014,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $35.89 | $8.28 |
| Revenue Next Year | $11.06 | $16.53 |
| P/E Ratio | $175.82 | ★ N/A |
| Revenue Growth | ★ 101.65 | 4.29 |
| 52 Week Low | $30.78 | $22.28 |
| 52 Week High | $66.74 | $59.55 |
Technical Indicators
Market Signals| Indicator | CELH | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 55.34 |
| Support Level | $37.45 | $23.74 |
| Resistance Level | $47.24 | $55.20 |
| Average True Range (ATR) | 2.21 | 3.56 |
| MACD | -0.36 | -0.50 |
| Stochastic Oscillator | 0.95 | 40.31 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.